267 related articles for article (PubMed ID: 31225971)
21. Personalized cancer vaccination in head and neck cancer.
Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
[TBL] [Abstract][Full Text] [Related]
22. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
24. [Personalized peptide vaccine for cancer treatment; now and its future].
Waki K; Yamada A
Nihon Rinsho; 2017 Feb; 75(2):251-256. PubMed ID: 30562860
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
26. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
27. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
28. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
29. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
30. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
31. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
32. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.
Koga N; Moriya F; Waki K; Yamada A; Itoh K; Noguchi M
Cancer Sci; 2017 Dec; 108(12):2326-2332. PubMed ID: 28898532
[TBL] [Abstract][Full Text] [Related]
33. Cancer vaccines: Targeting KRAS-driven cancers.
Zhang Y; Ma JA; Zhang HX; Jiang YN; Luo WH
Expert Rev Vaccines; 2020 Feb; 19(2):163-173. PubMed ID: 32174221
[No Abstract] [Full Text] [Related]
34. Immunotherapy in lung cancer: "b7-bombers" and other new developments.
Creelan BC; Antonia SJ
Semin Respir Crit Care Med; 2013 Dec; 34(6):810-21. PubMed ID: 24258571
[TBL] [Abstract][Full Text] [Related]
35. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
36. Personalized cancer neoantigen vaccines come of age.
Chu Y; Liu Q; Wei J; Liu B
Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
[TBL] [Abstract][Full Text] [Related]
37. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
38. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Sahin U; Derhovanessian E; Miller M; Kloke BP; Simon P; Löwer M; Bukur V; Tadmor AD; Luxemburger U; Schrörs B; Omokoko T; Vormehr M; Albrecht C; Paruzynski A; Kuhn AN; Buck J; Heesch S; Schreeb KH; Müller F; Ortseifer I; Vogler I; Godehardt E; Attig S; Rae R; Breitkreuz A; Tolliver C; Suchan M; Martic G; Hohberger A; Sorn P; Diekmann J; Ciesla J; Waksmann O; Brück AK; Witt M; Zillgen M; Rothermel A; Kasemann B; Langer D; Bolte S; Diken M; Kreiter S; Nemecek R; Gebhardt C; Grabbe S; Höller C; Utikal J; Huber C; Loquai C; Türeci Ö
Nature; 2017 Jul; 547(7662):222-226. PubMed ID: 28678784
[TBL] [Abstract][Full Text] [Related]
39. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
